ReviewCell adhesion & migration
NAD and axon degeneration: from the Wlds gene to neurochemistry.
Review in Cell adhesion & migration. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- Changes in Quality of Life Among Glaucoma Patients Following Six Months of Niacinamide Supplementation.Nutrients · 2025Article
- N-Acetylcysteine Ameliorates Loss of the Electroretinogram b-wave in a Bardet-Biedl Syndrome Type 10 Mouse Model.Journal of experimental neurology · 2025Article
- Epigenetic Orchestration of Neurodegenerative Disorders: A Possible Target for Curcumin as a Therapeutic.Neurochemical research · 2024Review
- Nicotinamide: Bright Potential in Glaucoma Management.Biomedicines · 2024Review
- Nicotinamide Prevents Retinal Vascular Dropout in a Rat Model of Ocular Hypertension and Supports Ocular Blood Supply in Glaucoma Patients.Investigative ophthalmology & visual science · 2023Article
- Downregulation of SF3B2 protects CNS neurons in models of multiple sclerosis.Annals of clinical and translational neurology · 2023Article
- Systemic Treatment with Nicotinamide Riboside Is Protective in Two Mouse Models of Retinal Ganglion Cell Damage.Pharmaceutics · 2021Article
- Neuroprotection in Glaucoma: NADCells · 2021Review
- Overexpression of Sirtuin 1 protein in neurons prevents and reverses experimental diabetic neuropathy.Brain : a journal of neurology · 2019Article
- Metabolic aspects of neuronal degeneration: From a NADNeuroscience research · 2019Review
- Role of mitochondria in diabetic peripheral neuropathy: Influencing the NADInternational review of neurobiology · 2019Review
- Nampt/RelB pathway protects learning and memory ability in aged rats after general anesthesia with sevoflurane and nitrous oxide.International journal of clinical and experimental pathology · 2018Article
- Proteomic profiling of neuronal mitochondria reveals modulators of synaptic architecture.Molecular neurodegeneration · 2017Article
- Glucose metabolism in nerve terminals.Current opinion in neurobiology · 2017Review
- Elevated mitochondria-coupled NAD(P)H in endoplasmic reticulum of dopamine neurons.Molecular biology of the cell · 2016Article
- The NAD(+) salvage pathway modulates cancer cell viability via p73.Cell death and differentiation · 2016Article
- Preserve and protect: maintaining axons within functional circuits.Trends in neurosciences · 2014Review
- Intracellular redox state revealed by in vivo (31) P MRS measurement of NAD(+) and NADH contents in brains.Magnetic resonance in medicine · 2014Article
- Nicotinamide adenine dinucleotide (NAD+) repletion attenuates bupivacaine-induced neurotoxicity.Neurochemical research · 2013Article
- Protective role of Wallerian degeneration slow (Wld(s)) gene against retinal ganglion cell body damage in a Wallerian degeneration model.Experimental and therapeutic medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases have become a global issue due to the aging population. These disorders affect a vast patient population and represent a huge area of unmet therapeutic need. Axon degeneration is a common pathological character of those neurodegenerative diseases. It results in the loss of communication between neurons. Two decades ago, the Wallerian degeneration slow (Wlds) mouse strain was identified, in which the degeneration of transected axons is delayed. The phenotype is attributed to the overexpression of a chimeric protein Wlds which contains a short fragment of the ubiquitin assembly protein UFD2 and the full-length nicotinamide adenine dinucleotide (NAD) synthetic enzyme Nicotinamide mononucleotide adenylyl-transferase-1 (Nmnat-1). However, the underlying molecular mechanism remains largely unknown. Recently, it's reported by independent researchers that the full length coding sequence of mouse Nmnat-1 could mimic the axonal protective effect of the Wlds gene when overexpressed in primary neural cultures. Together with a significant number of subsequential reports, this finding highlighted the substantial role of nicotinamide adenine dinucleotide (NAD) in the process of axon degeneration. Here we reviewed the history of axon degeneration research from a neurochemical standpoint and discuss the potential involvement of NAD synthesis, NAD consumption and NAD-dependent proteins and small molecules in axon degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.